Alan's €480M Series G: A fact-checked breakdown of the largest European healthtech round of 2026

On June 25, 2026, French health insurance company Alan announced a €480 million (~$550 million) Series G financing round, valuing the company at €5.5 billion ($6.3 billion) . The round was led by Prosus, the Amsterdam-listed global technology investor, which contributed €400 million ($460 million) of the total in a mix of primary and secondary equity . Existing investors Teachers' Venture Growth (Ontario Teachers' Pension Plan), Index Ventures, and Dara Holdings also participated . The closing of the round is subject to applicable regulatory approvals, including from French financial authorities .

Alan was founded in 2016 by Jean-Charles Samuelian-Werve and Charles Gorintin . The company operates a digital health insurance and AI-powered preventive healthcare platform, serving over 1.1 million members and 37,000 businesses across France, Spain, Belgium, and Canada . As of Q1 2026, Alan reported approximately €800 million in annual recurring revenue (ARR), representing 53% year-over-year growth, and the company is profitable in France . The company employs approximately 850 people .

Kylian Mbappé Partnership

In March 2026, Kylian Mbappé became a minority shareholder and brand ambassador for Alan through his investment fund Coalition Capital . Alan described the arrangement not as a sponsorship deal but as Mbappé joining the company as an "investor and teammate" who will be integrated into the product via Alan Play, where users can access health content linked to Mbappé's routines around sleep, nutrition, and mental health .

Use of Funds

Alan stated the funds will be deployed toward:

• International expansion into new European and global markets
• Deeper penetration in existing markets (France, Spain, Belgium, Canada)
• Strategic acquisitions to broaden capabilities
• AI healthcare innovation, particularly in prevention-focused insurance products

With a credible path toward €1 billion ARR by year-end 2026 , Alan's Series G signals continued investor appetite for AI-driven health insurance platforms that prioritize prevention over traditional sick-care models.